ANGLE sets hails growing pipeline of potential deals

ANGLE PLC, a liquid biopsy specialist, reported a growing pipeline of potential deals with major pharmaceutical and medical technology firms, including a "transformational" collaboration with Myriad Genetics and completed projects with AstraZeneca and Eisai, signaling progress for its Parsortix system. However, the company experienced financial headwinds in H1 2025, with revenue declining to £0.8 million and losses widening to £9.3 million, attributing this to challenging external conditions and limited access to capital. Despite these pressures and cash reserves of £5.3 million (expected to last into early 2026), ANGLE remains focused on capitalizing on ongoing high-profile discussions to drive long-term value.

Analysis

ANGLE PLC presents a classic case of a development-stage company with significant technological promise facing immediate financial headwinds. On the positive side, the company is advancing its commercial pipeline, highlighted by completed projects with major pharmaceutical firms like AstraZeneca and Eisai, and a new, potentially transformational collaboration with Myriad Genetics to adapt a cancer test for its Parsortix liquid biopsy system. Management has positioned this as a key step toward large-scale commercialization and routine clinical adoption. However, this strategic progress is starkly contrasted by deteriorating financial metrics. For the first half of 2025, revenue declined to £0.8 million from £1.0 million year-over-year, while the net loss widened to £9.3 million from £7.7 million. Management attributes these results to challenging external conditions, including trade tariff uncertainty and reduced access to capital, which are delaying customer projects. Critically, the company's cash position of £5.3 million, even with expected tax credits, provides a limited funding runway only into early 2026, creating a significant liquidity risk that overshadows the optimistic long-term outlook.

Key Decisions for Investors

• Investors should recognize the high-risk, high-reward profile of ANGLE, weighing the long-term potential of its Parsortix commercialization, particularly the Myriad Genetics deal, against immediate financial pressures and a short cash runway.
• Monitor for tangible progress in converting the touted deal pipeline into definitive, revenue-generating contracts, as this will be the primary catalyst to validate the company's strategy and counter the current cash burn.
• Given the funding runway only extends into early 2026, investors must closely track the company's burn rate and be prepared for a potential capital raise, which could be dilutive, especially in a market with constrained capital access.